# A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)

> **NCT02774239** · PHASE3 · COMPLETED · sponsor: **University of Alberta** · enrollment: 26 (actual)

## Conditions studied

- Myasthenia Gravis

## Interventions

- **DRUG:** Human normal immunoglobulin G (IgG)

## Key facts

- **NCT ID:** NCT02774239
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2022-10-21
- **Final completion:** 2022-10-21
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2023-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02774239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02774239, "A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02774239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*